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Abstract
Passive transfer of broadly neutralizing HIV antibodies can prevent infection, which suggests that
vaccines that elicit such antibodies would be protective. Thus far, however, few broadly
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neutralizing HIV antibodies that occur naturally have been characterized. To determine whether
these antibodies are part of a larger group of related molecules, we cloned 576 new HIV
antibodies from four unrelated individuals. All four individuals produced expanded clones of
potent broadly neutralizing CD4-binding-site antibodies that mimic binding to CD4. Despite
extensive hypermutation, the new antibodies shared a consensus sequence of 68 immunoglobulin
H (IgH) chain amino acids and arise independently from two related IgH genes. Comparison of
the crystal structure of one of the antibodies to the broadly neutralizing antibody VRC01 revealed
conservation of the contacts to the HIV spike.
Two to three years after infection, some HIV-infected patients develop serum antibodies that
can neutralize a broad spectrum of HIV viruses (1–4). Among the naturally occurring
monoclonal antibodies, VRC01, an antibody cloned from memory B cells that targets the
CD4-binding site (CD4bs) on the HIV envelope spike, is unusual in its potency and breadth
(5, 6). As do other HIV antibodies obtained by the single-cell antigen-capture method (7),
VRC01 shows high levels of somatic mutations that are essential for its activity (6–8). This
high frequency of mutation is a potential impediment to antibody identification, because the
mutated sequences may no longer be complementary to the primers used for
immunoglobulin gene amplification (9). To avert this potential problem, we developed a
new primer set specifically designed to address this problem (the 5′ primer is set farther
upstream to avoid the mutated region) (fig. S1A and table S1) (10). The new strategy was
tested by sorting single B cells from a patient with high titers of broadly neutralizing
antibodies (Pt 8) (table S2) that bind to an HIV gp120 core glycoprotein stabilized in the
CD4-bound conformation and lacking the variable (V loops 1 to 3) (2CC core) ( (fig. S1B)
(11, 12). In contrast to the resurfaced protein used to clone VRC01, which was designed to
focus on antibodies to the CD4bs, the 2CC core should capture additional antibodies
including those specific to the CD4-induced co-receptor–binding site (CD4i) (11, 12).
In side-by-side comparisons, the new primer set increased recovery of immunoglobulin H
(IgH) chains when compared with the original primer set (fig. S2, A and B) (9). As
expected, the antibodies obtained with the new primer set were more mutated (fig. S2, A and
C) (average 35.7 versus 19.8, P = 0.0013, and maximum 85 versus 50 for IgH ) and included
clones not found with the original primer set (fig. S2, A and B). Moreover, the new primers
also recovered VRC01-related antibodies from cDNA samples isolated from single cells that
had been sorted with the original YU2-gp140 trimer probe used to develop the single-cell
antibody-cloning method (7, 13) (fig. S3, A and B).
Four unrelated HIV-infected individuals showing high titers of broadly neutralizing
antibodies were examined by using the 2CC core (table S2 and fig. S4, A and B). Two of
these individuals, Pt 1 and Pt 3, had been studied previously, but their cloned antibodies
could not account for their serologic activity (7). From single sorted B cells representing 200
different B cell clones that were diversified by mutation in germinal centers, 576 antibodies
were obtained from a starting population of 1.5 × 105 IgG+ memory B cells (Fig. 1A and
table S3). Representative members of each expanded B cell clone were tested for binding to
gp120 and were all positive (Fig. 1, B and C; fig. S5; and table S3). The site of antibody
binding on the envelope spike was mapped by using mutant proteins that interfere with
either the CD4bs [gp120(D368R)] (14–16), or the CD4i site [gp120(I420R)] (17). [These
mutants have substitutions, respectively, Arg for Asp at position 368 and Arg for Ile at
position 420.] NIH45-46, which is a VRC01 variant, and antibodies 3BNC60, 8ANC131,
and 12A12 (antibodies selected on the basis of neutralizing activity, see below) (Fig. 1C, fig.
S5, and table S3) showed binding patterns similar to VRC01’s. Others, including 1B2530
and 8ANC195, could not be classified precisely solely on the basis of enzyme-linked
immunosorbent assay (ELISA). As expected from earlier studies on HIV envelope–specific
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antibodies (8), 65% of the antibodies isolated by using the 2CC core were polyreactive (fig.
S6) compared with 22.7% polyreactivity in healthy control memory B cells (18) and 17.3%
in gp140-negative B cells from HIV-positive controls (8). Somatic hypermutation was likely
required for development of high-affinity antigen binding and polyreactivity because
reversion of four representative antibodies to the corresponding germ line led to complete
loss of binding to YU2-gp140 (13) (fig. S6B and fig. S7, A to C).
HIV-neutralizing activity was measured in vitro by using an initial panel of eight viruses
including three tier 1 clade A, B, and C, and five tier 2 clade B envelope (Env) pseudovirus
variants (19, 20). The neutralizing activity of the antibodies was compared with VRC01 and
purified serum IgG from the donors (Fig. 2A, fig. S4, and table S4). A selection of 11
representative antibodies showing high levels of neutralizing activity (Fig. 2A and table S5)
were further tested on a panel of 15 additional tier 2 Env pseudovirus variants (Fig. 2B and
table S6), including five viruses that are resistant to VRC01 (Fig. 2B and table S6). Of all of
the antibodies tested, 88% showed some neutralizing activity, and six clones (RU01, 08, 10,
12, 16, and NIH45-46) contained antibodies that were highly potent and broad (Fig. 2 and
tables S4 and S6). These clones were also the most abundant among those captured by 2CC
core in each of the four patients studied (Fig. 1A and table S3). Five antibodies representing
four different broadly neutralizing founder B cell clones [clone RU01 (3BNC117 and
3BNC55), clone RU16 (12A12), clone RU12 (8ANC195), and NIH45-46] (table S5), were
tested against an expanded panel of 118 tier 2 viral isolates from all known clades, including
32 transmitted founder viruses (Fig. 2C and table S7) [VRC01 had previously been tested on
82 of these (6).] The most impressive of the new antibodies, 3BNC117, belonging to a clone
with 85 members (RU01), showed an 80% inhibitory concentration (IC80) on a combined
group of 95 tier 2 viruses of 1.4 μg/ml (median and geometric mean IC80 values 0.3μg/ml,
table S7B). When compared with the previously published VRC01 neutralization data, only
17 of the viruses tested were more sensitive to VRC01 than 3BNC117, and 3BNC117
showed greater breadth (Fig. 2, B and C, and tables S4, S6, and S7) (6). NIH45-46, a new
variant of VRC01, was more potent than VRC01 on 62 of the viruses tested but still less
potent than 3BNC117 (Fig. 2, B and C, and tables S4, S6, and S7) (6). Together, the new
antibodies neutralized 96% of the 118 viruses tested (table S7A). Finally, the best antibodies
were highly hypermutated, and this was essential for their breadth and potency (fig. S7D and
tables S4, S6, and S7).
Our cloning strategy captures antibodies produced by antigen-binding memory B cells in the
blood, but circulating antibodies are not produced by these cells; they originate instead from
plasma cells in the bone marrow (21). To determine whether the antibodies cloned from
memory B cells are also found in the bone marrow plasma cell compartment, we purified
plasma cells from paired bone marrow samples from patients 3 and 8 (table S2 and fig. S8A)
and used polymerase chain reaction (PCR) to specifically amplify IgVH genes from the
clones RU01 and RU10 from memory B cells in these individuals (Fig. 2A, fig. S8A, and
table S3). Members of these clones and large numbers of additional variants were readily
identified in the respective plasma cell samples (fig. S8, B and C). We also verified that
antibodies from clones RU01, RU08, and RU10 (Fig. 2A and table S3) are found in serum
by mass spectrometry (fig. S9 and table S8).
To determine whether antibody affinity to gp120 is related to neutralizing activity, we
compared the binding of the highly active antibodies, selected clonal relatives, and germ
line–reverted progenitors by using surface plasmon resonance (SPR) (Fig. 3, A and B; figs.
S7B and S10; and table S9). The top neutralizing antibodies (tables S4 to S7) showed
affinities (KA) ranging from ≃107 to 1012 (M−1) to YU2-gp140 trimers (13) and ≃107 to
1011 (M−1) to the 2CC core (11) (Fig. 3, A and B, and tables S4, S6 and S9). Consistent with
their decreased neutralizing potency and breadth, 3BNC66, 3BNC156, and 3BNC55
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displayed lower affinities to the YU2-gp140 trimer than 3BNC117, but surprisingly, the
affinities of these antibodies to 2CC core did not correlate with their neutralizing activity
(Fig. 2, fig. S10, and tables S4 and S9). Finally, we were unable to detect binding by any of
the germ line–reverted antibodies tested (Fig. 3B, fig. S7B, and table S9). We conclude that
the antibodies captured by the 2CC core tend to show higher affinity to the YU2-gp140
trimer than to the 2CC core.
When VRC01 binds to the HIV spike, it produces large conformational changes that mimic
CD4 binding and expose the CD4i site (6). By contrast, the broadly neutralizing antibody
b12 (22) and many other known CD4bs antibodies do not (23). To determine whether the
ability to mimic CD4 is a shared feature of the most potent antibodies (tables S4 to S7), we
expressed two different HIV spikes (24) on the surface of human embryonic kidney–293
(HEK 293T) cells and measured CD4i-antibody binding in the presence or absence of CD4
or CD4bs antibodies (Fig. 3C). With one exception, all of the antibodies tested resemble
CD4 and VRC01 in that they facilitate CD4i-antibody binding to one or both viral spikes
(Fig. 3C and fig. S11). The only antibody tested that did not share this characteristic,
8ANC195, was not a traditional CD4bs antibody in that it was equally sensitive to the
D368R and I420R mutations (Fig. 1C and table S3), and it differed from the others in its
neutralization pattern (Fig. 2, A and B; and tables S4, S6, and S7).
To determine whether highly active CD4bs antibodies share common sequence features, we
aligned the 10 best antibodies (table S5): two variants each from independently derived
antibody clones arising in each of the four patients studied and from NIH45 (Fig. 4, A and
B; table S2; and fig. S3) (6). Comparison of the IgVH regions revealed a conserved
consensus sequence covering 68 IgVH residues (Fig. 4A). It is noteworthy that the IgVH
consensus contains seven VRC01-gp120 contact residues, including Arg 71VRC01, which
mimics the key interaction of Arg59CD4 and Asp368gp120 (Fig. 4A) (5, 25). All 10
antibodies arise from only two closely related germline IgVH genes that conserve six contact
residues (Fig. 4A, fig. S12A, and table S3). The codons of the consensus residues are highly
somatically mutated in the 10 selected antibodies; however, the ratio of replacement to silent
mutations in the consensus residues ranges from 0.7 to 1.7, whereas it is 3.5 to 22 in the
nonconsensus residues, which together indicate that conservation of the consensus is
strongly selected (fig. S13 and table S10). The light chain of VRC01 makes fewer contacts
with gp120 (5). Consistent with its more limited role, comparison of the light-chain
sequences of the same antibodies uncovers a less-extensive consensus covering 53 residues
from the variable region of immunoglobulin light chain (VL residues), which includes three
VRC01-gp120 contact residues (Fig. 4B and fig. S3B). Finally, like the heavy chains, the
light chains arise from a limited set of germ-line genes: Two are derived from IgK1D-33,
two from IgK3-11, and one from IgL1-47 (Fig. 4B, fig. S12B, and table S3) (5). Antibody
8ANC195, which differed from the others in several important respects (Figs. 1C, 2B, and
3C; fig. S11; and tables S4, S6, and S7), did not entirely conform to the consensus and did
not arise from related heavy or light chains (Fig. 4, A and B; fig. S14; and table S3). Thus,
there is significant sequence convergence among highly active agonistic CD4bs antibodies
(HAADs).
To determine whether the structure of the antibodies in different patients is also conserved,
we solved the crystal structure of the 3BNC60 Fab to 2.65 Å resolution and compared it
with VRC01’s (26) (Fig. 4, C to E). Superimposition of domains in the variable region of
immunoglobulin heavy chain (VH domains) from 3BNC60 and VRC01 in the VRC01-
gp120 cocrystal structure (5) yields a root mean square deviation (RMSD) of 1.3 Å
(calculated for 111 Cα atoms) with major differences confined to CDR2 residues 58 to 65
(3BNC60 numbering). Superimposing the structures suggests conservation of the
recognition interface with gp120 (Fig. 4D). For example, Arg723BNC60 adopts a similar
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conformation as Arg71VRC01, which mimics an important salt bridge normally formed
between Arg59CD4 and Asp368gp120 (5, 25). Gln653BNC60, which corresponds to
Gln64VRC01, is within the residue segment (residues 58 to 65) that differs in structure from
VRC01. The conformation of this region of 3BNC60, which is involved in a lattice contact
in the crystals, is likely to change upon binding gp120, as it would clash with the CD4-
binding loop on gp120. Superimposing the 3BNC60 and VRC01 VL domains yields a
RMSD of 0.9Å (calculated for 95 Cα atoms) and shows that some of gp120-contacting
residues are structurally conserved (Fig. 4E); Tyr913BNC60 and Glu903BNC60 adopt similar
conformations as Tyr91VRC01 and Glu96VRC01, which engage loop D of gp120 via polar
interactions (Fig. 4E). The VH and VL domains of the two Fabs show similar interdomain
interactions and overall orientation, as super-imposition of the VH and VL domains of
3BNC60 and VRC01 yields an RMSD of 1.4 Å (calculated for 206 Cα atoms). Overall,
these structural comparisons suggest that 3BNC60 binds gp120 with the same architecture
as observed for the binding of VRC01 (5).
Our experiments define a class of agonistic CD4bs antibodies, HAADs, that shares IgVH
and IgVL consensus sequences including 10 of the contact residues between VRC01 and the
HIV spike (Fig. 4, A and B). In five different donors, these antibodies originate from only
two closely related IgVH and three IgVL genes (Fig 4, A and B). Although we cannot
exclude the possibility that by using the 2CC core as bait for single-cell sorting might
introduce a selection bias, gp140 sorts performed on two of the donors did not reveal
additional broadly neutralizing antibodies (tables S3, E and F, and S4), which suggests that a
significant fraction of the CD4bs-directed repertoire was captured in our experiments. Thus,
the repertoire of antibodies that are available to solve the problem of broad and potent HIV
neutralization by binding to the CD4bs appears to be somewhat restricted. Despite this
restriction, HAADs account for a significant fraction of the memory B cell, and plasma cell
compartments, and the circulating IgGs in the patients tested. Therefore, HAADs are not
rare, and once elicited, they contribute to the circulating antibody pool in patients that
neutralize the virus broadly. However, HAADs are not found in all patients with high titers
of broad neutralizing activity (1, 27, 28). Moreover, broad neutralization can be achieved by
targeting epitopes other than the CD4bs (29–34) or by combinations of antibodies to
different epitopes (7, 35), or even combination of different CD4bs antibodies (table S7).
The high levels of neutralizing activity displayed by HAADs appear to be correlated with
binding to a specific surface, which is similar, but not identical, to that contacted by CD4 (5,
36). Why a specific type of binding that mimics CD4 appears to be required is not known
(6); however, it has been suggested that binding of soluble CD4, or CD4 mimetic
compounds, to the HIV envelope trimer leads to the formation of a metastable intermediate
that decays rapidly and loses the ability to fuse (37). We speculate that HAAD binding
mimics soluble CD4 and destabilizes the trimer. Irrespective of their mechanism of action,
HAADs might contribute to viremic control in a subset of HIV-infected individuals and may
be useful in HIV prevention, or possibly even therapy, because of the low concentrations
required for viral neutralization.
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The 2CC core captures CD4bs antibodies. (A and B) Top line indicates bait used for sorting,
and below is the patient number. The number in the center of the pies denotes the number of
antibodies; slices are unique clones and are proportional to clone size. Membership of an
antibody in a B cell clone is determined by sequence analysis, in particular CDR3s and
shared V and J genes of paired heavy- and light-chain genes (table S3). (A) Pie charts show
a summary of detected B cell clones irrespective of their binding epitopes. (★) Star indicates
clones found in both YU2-gp140 and 2CC core–sorted cells. (B) Pie charts show the
distribution of antibodies binding to CD4bs, CD4i, CD4ind. (equally affected by D368R and
I420R), and core (not affected by either D368R or I420R). Dashed lines indicate antibodies
that were cloned but could not be produced. (C) Representative ELISAs on YU2-gp120,
mutants, and 2CC core.
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Antibodies captured by 2CC core have broad and potent HIV-neutralizing activity. (A) HIV-
neutralizing activity assayed on a limited panel of viruses. Top line indicates the donor
number (table S2). Antibody clones are grouped, and individual clonal relatives are
represented by a column grouped as in table S4. Each row represents one virus as indicated
on the left. Colors indicate concentration of clones at the median inhibitory concentration
(IC50): red, ≤0.1 μg/ml; orange, 0.1 to 1 μg/ml; yellow, 1 to 10 μg/ml; green, ≥10 μg/ml;
and white, not neutralized at any concentration tested. (★) Star indicates the representatives
selected for the extended virus panel (table S5). (B) HIV-neutralizing activity assayed on an
extended panel of viruses (tables S5 and S6). (C) Neutralization summary graph comparing
the published IC50 values of VRC01 (6) with NIH45-46 and 3BNC117 (tables S5 and S7).
Each color represents a different HIV clade (black corresponds to CRF01AE, blue to clade
B, green to clade G, pink to clade D, gray to clade CD, emerald to clade C, brown to clade
ACD, magenta to clade AC, red to clade A, and orange to CRF02AG). Length of lines and
size of circles are inversely proportional to IC50. The distance between the outer and inner
circle, as well as from the inner circle to the center of the spiders, in each span is two logs in
IC50 concentration.
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Binding properties of antibodies. (A) Representative SPR sensor-grams for binding to YU2-
gp140 and 2CC core by 12A12, 12A21 (Fig. 2B and table S5), and 12A germ line (GL)–
reverted antibodies. (B) Graph shows KA for representative antibodies (tables S5 and S9).
(C) Graph shows mean fluorescence intensity of CD4i antibody 3-67 (7) binding to Bal-
expressing 293T cells after incubation with the indicated antibodies. Table indicates whether
or not an antibody induces CD4i site accessibility (fig. S11).
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Sequence and structural conservation of HAADs. (A) Amino acid alignment of 10 selected
HAADs (table S5), their germline genes, and 8ANC195. Residues are numbered according
to the 3BNC60 structure. Framework (FR) and CDR regions are indicated. Red shading
shows amino acid identity; yellow shows biochemical similarity. The consensus is defined
by 70% similarity between the 10 selected HAADs. The consensus sequence is shown
above; dashes in this sequence indicate nonconserved residues. Contact residues between
VRC01 and gp120 are shown above the consensus as closed circles for main-and side-chain
interactions, open circles main chain only, and stars side chains only (5). (B) As in (A) for
light chains. (C, D, and E) Crystal structure of 3BNC60 Fab. (C) Superimposed Cα traces of
the two Fab molecules in the 3BNC60 asymmetric unit are shown in green and red.
Semitransparent surfaces are used to outline the heavy (cyan) and light (gray) chains. (D)
Superimposition of the 3BNC60 VH (red, Cα trace) and VRC01 VH (cyan, Cα trace) shown
with a ribbon representation of the CD4-binding loop. The salt bridge between Arg71VRC01
and Asp368gp120 is shown as dashed lines. (E) Superimposition of the 3BNC60 VL (red, Cα
trace). Hydrogen bonds between VRC01 and gp120 are shown as dashed lines.
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